---
document_datetime: 2025-12-02 05:53:52
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/translarna.html
document_name: translarna.html
version: success
processing_time: 0.1383164
conversion_datetime: 2025-12-25 07:29:51.320579
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Translarna

[RSS](/en/individual-human-medicine.xml/66330)

##### Expired

This medicine's authorisation has expired

ataluren Medicine Human Expired

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Translarna](#news-on)
- [Related content](#related-content-69745)
- [More information on Translarna](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 28 March 2025, the European Commission issued a decision to not renew the conditional marketing authorisation for Translarna (ataluren) in the European Union (EU). The marketing authorisation holder for the medicine was PTC Therapeutics International Limited.

The non-renewal of the marketing authorisation follows the opinion issued by EMA's human medicines committee, CHMP, which recommended to not renew the authorisation because the effectiveness of the medicine has not been confirmed.

Further information is available in the [news announcement](https://www.ema.europa.eu/en/news/translarna-ema-re-confirms-non-renewal-authorisation-duchenne-muscular-dystrophy-medicine) published at the time of the CHMP opinion.

Translarna was granted marketing authorisation in the EU on 31 July 2014 for the treatment of Duchenne muscular dystrophy.

The European Public Assessment Report (EPAR) for Translarna will be updated to indicate that the marketing authorisation is no longer valid.

Translarna : EPAR - Medicine overview

English (EN) (200.42 KB - PDF)

**First published:** 04/09/2014

**Last updated:** 16/04/2025

[View](/en/documents/overview/translarna-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-201)

български (BG) (261.88 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/bg/documents/overview/translarna-epar-medicine-overview_bg.pdf)

español (ES) (186.37 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/es/documents/overview/translarna-epar-medicine-overview_es.pdf)

čeština (CS) (234.36 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/cs/documents/overview/translarna-epar-medicine-overview_cs.pdf)

dansk (DA) (178.18 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/da/documents/overview/translarna-epar-medicine-overview_da.pdf)

Deutsch (DE) (191.77 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/de/documents/overview/translarna-epar-medicine-overview_de.pdf)

eesti keel (ET) (173.11 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/et/documents/overview/translarna-epar-medicine-overview_et.pdf)

ελληνικά (EL) (270.66 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/el/documents/overview/translarna-epar-medicine-overview_el.pdf)

français (FR) (191.03 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/fr/documents/overview/translarna-epar-medicine-overview_fr.pdf)

hrvatski (HR) (224.07 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/hr/documents/overview/translarna-epar-medicine-overview_hr.pdf)

italiano (IT) (184.74 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/it/documents/overview/translarna-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (237.26 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/lv/documents/overview/translarna-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (229.37 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/lt/documents/overview/translarna-epar-medicine-overview_lt.pdf)

magyar (HU) (217.82 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/hu/documents/overview/translarna-epar-medicine-overview_hu.pdf)

Malti (MT) (232.94 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/mt/documents/overview/translarna-epar-medicine-overview_mt.pdf)

Nederlands (NL) (187.05 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/nl/documents/overview/translarna-epar-medicine-overview_nl.pdf)

polski (PL) (232.51 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/pl/documents/overview/translarna-epar-medicine-overview_pl.pdf)

português (PT) (188.87 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/pt/documents/overview/translarna-epar-medicine-overview_pt.pdf)

română (RO) (238.38 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/ro/documents/overview/translarna-epar-medicine-overview_ro.pdf)

slovenčina (SK) (224.98 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/sk/documents/overview/translarna-epar-medicine-overview_sk.pdf)

slovenščina (SL) (225.79 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/sl/documents/overview/translarna-epar-medicine-overview_sl.pdf)

Suomi (FI) (175.98 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/fi/documents/overview/translarna-epar-medicine-overview_fi.pdf)

svenska (SV) (180.78 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/sv/documents/overview/translarna-epar-medicine-overview_sv.pdf)

Translarna : EPAR - Risk-management-plan summary

English (EN) (274.32 KB - PDF)

**First published:** 04/09/2014

**Last updated:** 16/04/2025

[View](/en/documents/rmp-summary/translarna-epar-risk-management-plan-summary_en.pdf)

Translarna : EPAR - Risk-management-plan summary

English (EN) (803.97 KB - PDF)

**First published:** 30/07/2019

**Last updated:** 16/04/2025

[View](/en/documents/rmp-summary/translarna-epar-risk-management-plan-summary_en.pdf-0)

## Product information

Translarna : EPAR - Product Information

English (EN) (1.81 MB - PDF)

**First published:** 04/09/2014

**Last updated:** 16/04/2025

[View](/en/documents/product-information/translarna-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-762)

български (BG) (2.04 MB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/bg/documents/product-information/translarna-epar-product-information_bg.pdf)

español (ES) (1.89 MB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/es/documents/product-information/translarna-epar-product-information_es.pdf)

čeština (CS) (2.06 MB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/cs/documents/product-information/translarna-epar-product-information_cs.pdf)

dansk (DA) (1.74 MB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/da/documents/product-information/translarna-epar-product-information_da.pdf)

Deutsch (DE) (1.93 MB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/de/documents/product-information/translarna-epar-product-information_de.pdf)

eesti keel (ET) (1.81 MB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/et/documents/product-information/translarna-epar-product-information_et.pdf)

ελληνικά (EL) (2.44 MB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/el/documents/product-information/translarna-epar-product-information_el.pdf)

français (FR) (2.22 MB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/fr/documents/product-information/translarna-epar-product-information_fr.pdf)

hrvatski (HR) (2.16 MB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/hr/documents/product-information/translarna-epar-product-information_hr.pdf)

íslenska (IS) (1.8 MB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/is/documents/product-information/translarna-epar-product-information_is.pdf)

italiano (IT) (1.82 MB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/it/documents/product-information/translarna-epar-product-information_it.pdf)

latviešu valoda (LV) (2.27 MB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/lv/documents/product-information/translarna-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.11 MB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/lt/documents/product-information/translarna-epar-product-information_lt.pdf)

magyar (HU) (2.4 MB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/hu/documents/product-information/translarna-epar-product-information_hu.pdf)

Malti (MT) (2.6 MB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/mt/documents/product-information/translarna-epar-product-information_mt.pdf)

Nederlands (NL) (1.91 MB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/nl/documents/product-information/translarna-epar-product-information_nl.pdf)

norsk (NO) (1.71 MB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/no/documents/product-information/translarna-epar-product-information_no.pdf)

polski (PL) (2.05 MB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/pl/documents/product-information/translarna-epar-product-information_pl.pdf)

português (PT) (1.7 MB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/pt/documents/product-information/translarna-epar-product-information_pt.pdf)

română (RO) (1.97 MB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/ro/documents/product-information/translarna-epar-product-information_ro.pdf)

slovenčina (SK) (1.96 MB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/sk/documents/product-information/translarna-epar-product-information_sk.pdf)

slovenščina (SL) (1.91 MB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/sl/documents/product-information/translarna-epar-product-information_sl.pdf)

Suomi (FI) (1.88 MB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/fi/documents/product-information/translarna-epar-product-information_fi.pdf)

svenska (SV) (1.74 MB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/sv/documents/product-information/translarna-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0071 28/10/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Translarna : EPAR - All Authorised presentations

English (EN) (58.52 KB - PDF)

**First published:** 04/09/2014

**Last updated:** 16/04/2025

[View](/en/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-423)

български (BG) (70.29 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/bg/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_bg.pdf)

español (ES) (48.68 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/es/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_es.pdf)

čeština (CS) (60.17 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/cs/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (49.1 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/da/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (50.01 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/de/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (62.59 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/et/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (69.68 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/el/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_el.pdf)

français (FR) (48.73 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/fr/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (62.85 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/hr/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (48.73 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/is/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_is.pdf)

italiano (IT) (47.93 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/it/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (64.28 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/lv/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (63.91 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/lt/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (64.98 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/hu/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (66.27 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/mt/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (59.15 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/nl/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (48.97 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/no/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_no.pdf)

polski (PL) (73.52 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/pl/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_pl.pdf)

português (PT) (63.81 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/pt/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_pt.pdf)

română (RO) (58.6 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/ro/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (60.26 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/sk/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (59.5 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/sl/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (63.27 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/fi/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (48.54 KB - PDF)

**First published:**

04/09/2014

**Last updated:**

16/04/2025

[View](/sv/documents/all-authorised-presentations/translarna-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Translarna Active substance ataluren International non-proprietary name (INN) or common name ataluren Therapeutic area (MeSH) Muscular Dystrophy, Duchenne Anatomical therapeutic chemical (ATC) code M09AX03

### Pharmacotherapeutic group

Other drugs for disorders of the musculo-skeletal system

### Therapeutic indication

Translarna is indicated for the treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. Efficacy has not been demonstrated in non-ambulatory patients.

The presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.

## Authorisation details

EMA product number EMEA/H/C/002720

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Marketing authorisation holder

PTC Therapeutics International Limited

Unit 1 52-55 Sir John Rogerson's Quay Dublin 2 D02 NA07 Ireland

Opinion adopted 23/01/2014 Marketing authorisation issued 31/07/2014 Expiry of marketing authorisation 28/03/2025 Revision 25

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Translarna : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (904.2 KB - PDF)

**First published:** 28/11/2014

**Last updated:** 16/04/2025

[View](/en/documents/procedural-steps-after/translarna-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Translarna-H-C-2720-R-0071 : EPAR - Assessment Report - Non-renewal

Adopted

Reference Number: EMA/CHMP/555483/2024

English (EN) (6.54 MB - PDF)

**First published:** 14/04/2025

**Last updated:** 16/04/2025

[View](/en/documents/variation-report/translarna-h-c-2720-r-0071-epar-assessment-report-non-renewal_en.pdf)

Translarna-H-C-002720-II-0074 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/116346/2024

English (EN) (1.48 MB - PDF)

**First published:** 15/04/2024

**Last updated:** 16/04/2025

[View](/en/documents/variation-report/translarna-h-c-002720-ii-0074-epar-assessment-report-variation_en.pdf)

Translarna-H-C-2720-P46-028 : EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/597049/2021

English (EN) (928 KB - PDF)

**First published:** 10/02/2022

**Last updated:** 16/04/2025

[View](/en/documents/variation-report/translarna-h-c-2720-p46-028-epar-assessment-report_en.pdf)

Translarna-H-C-2720-II-0047 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/616402/2019

English (EN) (7.6 MB - PDF)

**First published:** 18/12/2019

**Last updated:** 16/04/2025

[View](/en/documents/variation-report/translarna-h-c-2720-ii-0047-epar-assessment-report-variation_en.pdf)

Translarna-H-C-2720-P46-0025 : EPAR - Assessment Report

Adopted

Reference Number: EMA/649891/2019

English (EN) (938.84 KB - PDF)

**First published:** 02/12/2019

**Last updated:** 16/04/2025

[View](/en/documents/variation-report/translarna-h-c-2720-p46-0025-epar-assessment-report_en.pdf)

Questions and answers on the refusal of a change to the marketing authorisation for Translarna (ataluren)

Adopted

Reference Number: EMA/565599/2019

English (EN) (158.55 KB - PDF)

**First published:** 28/06/2019

**Last updated:** 16/04/2025

[View](/en/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_en.pdf)

[Other languages (22)](#file-language-dropdown-33)

български (BG) (218.19 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

16/04/2025

[View](/bg/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_bg.pdf)

español (ES) (161.38 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

16/04/2025

[View](/es/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_es.pdf)

čeština (CS) (191.68 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

16/04/2025

[View](/cs/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_cs.pdf)

dansk (DA) (158.99 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

16/04/2025

[View](/da/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_da.pdf)

Deutsch (DE) (163.18 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

16/04/2025

[View](/de/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_de.pdf)

eesti keel (ET) (146.09 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

16/04/2025

[View](/et/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_et.pdf)

ελληνικά (EL) (233.06 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

16/04/2025

[View](/el/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_el.pdf)

français (FR) (165.91 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

16/04/2025

[View](/fr/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_fr.pdf)

hrvatski (HR) (189.65 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

16/04/2025

[View](/hr/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_hr.pdf)

italiano (IT) (160.32 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

16/04/2025

[View](/it/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_it.pdf)

latviešu valoda (LV) (190.24 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

16/04/2025

[View](/lv/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_lv.pdf)

lietuvių kalba (LT) (202.91 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

16/04/2025

[View](/lt/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_lt.pdf)

magyar (HU) (186.98 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

16/04/2025

[View](/hu/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_hu.pdf)

Malti (MT) (206.31 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

16/04/2025

[View](/mt/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_mt.pdf)

Nederlands (NL) (162.28 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

16/04/2025

[View](/nl/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_nl.pdf)

polski (PL) (200.92 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

16/04/2025

[View](/pl/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_pl.pdf)

português (PT) (162.58 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

16/04/2025

[View](/pt/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_pt.pdf)

română (RO) (197.35 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

16/04/2025

[View](/ro/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_ro.pdf)

slovenčina (SK) (187.57 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

16/04/2025

[View](/sk/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_sk.pdf)

slovenščina (SL) (190.25 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

16/04/2025

[View](/sl/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_sl.pdf)

Suomi (FI) (148.09 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

16/04/2025

[View](/fi/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_fi.pdf)

svenska (SV) (153.27 KB - PDF)

**First published:**

28/06/2019

**Last updated:**

16/04/2025

[View](/sv/documents/smop/questions-answers-refusal-change-marketing-authorisation-translarna-ataluren_sv.pdf)

Translarna-H-C-2720-II-0049 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/159564/2019

English (EN) (1.95 MB - PDF)

**First published:** 07/03/2019

**Last updated:** 16/04/2025

[View](/en/documents/variation-report/translarna-h-c-2720-ii-0049-epar-assessment-report-variation_en.pdf)

Translarna-H-C-2720-II-0037 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/431114/2018

English (EN) (5.72 MB - PDF)

**First published:** 31/08/2018

**Last updated:** 16/04/2025

[View](/en/documents/variation-report/translarna-h-c-2720-ii-0037-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Translarna (II-37)

Adopted

Reference Number: EMA/304289/2018

English (EN) (143.03 KB - PDF)

**First published:** 01/06/2018

**Last updated:** 16/04/2025

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-translarna-ii-37_en.pdf)

Translarna-H-C-2720-R-0022 : EPAR - Assessment Report - Renewal

Adopted

Reference Number: EMA/CHMP/738638/2016

English (EN) (993.84 KB - PDF)

**First published:** 08/03/2017

**Last updated:** 16/04/2025

[View](/en/documents/variation-report/translarna-h-c-2720-r-0022-epar-assessment-report-renewal_en.pdf)

## Initial marketing authorisation documents

Translarna : EPAR - Public assessment report

Adopted

Reference Number: EMA/369266/2014

English (EN) (4.14 MB - PDF)

**First published:** 04/09/2014

**Last updated:** 16/04/2025

[View](/en/documents/assessment-report/translarna-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Translarna

Adopted

Reference Number: EMEA/CHMP/310130/2014

English (EN) (649.08 KB - PDF)

**First published:** 23/05/2014

**Last updated:** 16/04/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-translarna_en.pdf)

#### News on Translarna

[Translarna: EMA re-confirms non-renewal of authorisation of Duchenne muscular dystrophy medicine](/en/news/translarna-ema-re-confirms-non-renewal-authorisation-duchenne-muscular-dystrophy-medicine) 18/10/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-october-2024) 18/10/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024) 26/07/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024) 28/06/2024

[EMA recommends non-renewal of authorisation of Duchenne muscular dystrophy medicine Translarna](/en/news/ema-recommends-non-renewal-authorisation-duchenne-muscular-dystrophy-medicine-translarna-0) 28/06/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-january-2024) 26/01/2024

[EMA confirms recommendation for non-renewal of authorisation of Duchenne muscular dystrophy medicine Translarna](/en/news/ema-confirms-recommendation-non-renewal-authorisation-duchenne-muscular-dystrophy-medicine-translarna) 26/01/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-october-2023) 13/10/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2023) 15/09/2023

[EMA recommends non-renewal of authorisation of Duchenne muscular dystrophy medicine Translarna](/en/news/ema-recommends-non-renewal-authorisation-duchenne-muscular-dystrophy-medicine-translarna) 15/09/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-october-2019) 18/10/2019

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2019) 26/07/2019

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2019) 28/06/2019

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 May 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-may-2018) 01/06/2018

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 March 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-march-2017) 24/03/2017

[Release of documents on two medicines temporarily halted](/en/news/release-documents-two-medicines-temporarily-halted) 14/03/2017

[Small and medium-sized enterprises: driving innovation in medicines](/en/news/small-medium-sized-enterprises-driving-innovation-medicines) 29/09/2014

[European Medicines Agency recommends 39 medicines for human use for marketing authorisation in first half of 2014](/en/news/european-medicines-agency-recommends-39-medicines-human-use-marketing-authorisation-first-half-2014) 10/07/2014

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 May 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-may-2014) 23/05/2014

[European Medicines Agency recommends first-in-class medicine for treatment of Duchenne muscular dystrophy](/en/news/european-medicines-agency-recommends-first-class-medicine-treatment-duchenne-muscular-dystrophy) 23/05/2014

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 February 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-february-2014) 21/02/2014

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 January 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-january-2014) 24/01/2014

#### Related content

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-278) on 27 May 2005. Translarna was withdrawn from the Community register of orphan medicinal products in August 2024 at the end of the 10-year period of market exclusivity.

#### More information on Translarna

- [EMEA-000115-PIP01-07-M13 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000115-pip01-07-m13)
- [EMEA-000115-PIP02-09-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000115-pip02-09-m03)
- [Translarna - withdrawal of application for variation to marketing authorisation](/en/medicines/human/variation/translarna)
- [Long-Term Observational study of Translarna Safety and Effectiveness in Usual Care (STRIDE) - post-authorisation study](https://catalogues.ema.europa.eu/study/48265)

**This page was last updated on** 29/10/2024

## Share this page

[Back to top](#main-content)